Incyte gets milestone payment from Lilly for drug in Phase III program

110
Advertisement

Incyte Corporation, Wilmington, has earned a $50 million milestone payment from Eli Lilly and Company based on the formal initiation of the rheumatoid arthritis RA Phase III program for baricitinib.

The Phase III program is being conducted by Lilly as part of the exclusive agreement for baricitinib.

Four Phase III  studies are planned, which will investigate the safety and  effectiveness  of baricitinib 2 mg and 4 mg once daily in patients with active  rheumatoid arthritis. Patients completing any of the four studies will be eligible for enrollment in a fifth study, a long-term extension.

Incyte is a  biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs for cancer  and inflammation. For additional information, visit www.incyte.com.

 

Advertisement
Advertisement
Advertisement